Unknown PHASE4 INTERVENTIONAL 2-arm NCT01572597

Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy

Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy.

Sponsor: Buddhist Tzu Chi General Hospital

Conditions Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

Interventions 10RAC+acetylcystein 10RAC+metronidazole

Updated 6 times since 2017 Last updated: Apr 5, 2012 Started: Jun 30, 2011 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Bacterial Infection Due to Helicobacter Pylori (H. Pylori) and is currently ongoing. Buddhist Tzu Chi General Hospital leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Buddhist Tzu Chi General Hospital

Data source: Buddhist Tzu Chi General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hualien City, Taiwan